HOME >> BIOLOGY >> NEWS
Sea creature's toxin could lead to promising cancer treatment

tinguishable in its biological action, but is easier to synthesize in the lab.

The researchers tested AB-5's effectiveness against cancer by implanting human tumor cells under the skin of m ice and treating them with either paclitaxel (Taxol) or vinblastine both approved drugs currently used or AB-5. The trial used tumor cells from human prostate, breast and colon cancers.

While all three drugs reduced tumors in the mice, the known drugs caused significant weight loss and loss of white blood cells while AB-5 caused neither side effect. "That the diazonamide toxin blocks mitosis selectively in cancer cells is almost too desirable an outcome to be true," said Dr. Steven McKnight, chairman of biochemistry and senior author of the second study. "As with any other unanticipated scientific discovery, the validity of these observations will be held to appropriately diligent scrutiny."


'"/>

Contact: Aline McKenzie
aline.mckenzie@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
5-Feb-2007


Page: 1 2 3

Related biology news :

1. New use for a cell toxin found to inhibit survival proteins in cancer cells
2. Children of smokers have more than 5 times higher levels of a nicotine toxin
3. Genome of Clostridium botulinum reveals the background to worlds deadliest toxin
4. Engineered protein effective against Staphylococcus aureus toxin
5. Anthrax paralyzes immune cells with lethal toxin, UF research shows
6. Gene that governs toxin production in deadly mold found
7. Bacterial response to oxidation studied as toxin barometer
8. Scripps research scientists: Compounds show significant promise against potential bioweapon toxins
9. Algae toxin identification unravels fish-kill mystery
10. Red tide toxins leave beachgoers breathless
11. Study reveals molecular basis of botulism toxins deadly activity

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Sea creature toxin could lead promising cancer treatment

(Date:6/24/2015)... June 24, 2015 The biologics safety testing ... drivers for the market include growth of the pharmaceutical ... drug launches. Over the years, the number of drug ... and 2010, the FDA approved 225 drug applications and ... Europe accounted for 3,822 of ...
(Date:6/24/2015)... Switzerland , June 24, 2015 ... partnership with emerging biometric password solution one face ... one face in, entering ... a ground-breaking and affordable multifactor-authentication biometric answer to ... recognition technology, provided in partnership with KeyLemon, one ...
(Date:6/23/2015)... PALM BEACH GARDENS, Fla. , June ... of multi-factor identity management and authentication solutions, today ... Altus strong, multi-factor authentication solution.  The ... ease of use of the DigitalPersona Altus ... and biometric reader compatibility. In ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2
(Date:6/30/2015)... , ... June 30, 2015 , ... Matrix Marketing ... that it has hired Gem Swartz to head up its account management department as ... director. Both Gem and Amanda bring senior account management and delivery expertise to the ...
(Date:6/30/2015)... VANCOUVER , June 30, 2015 /PRNewswire/ - ... a clinical stage regenerative medicine company focused on ... the first participant in its Phase 1/2 clinical ... of chronic unilateral Achilles tendinosis, has been enrolled ... to intra-tendon ultrasound-guided injections. RCT-01 is comprised of ...
(Date:6/30/2015)... ... 30, 2015 , ... Smarter Alloys today announced a final ... that allows orthodontists to simultaneously apply different forces to different teeth. The additional ... thrilled about taking SmartArch one step closer to commercial availability for orthodontists and ...
(Date:6/29/2015)... , June 30, 2015   Pharnext SAS ... being developed for the treatment of Charcot-Marie-Tooth Type 1A (CMT1A), ... at the 2015 Peripheral Nerve Society (PNS) Biennial Meeting at ... , June 27 - July 2, 2015. ... on Wed July 1, 5p.m. to 7p.m. EDT: ...
Breaking Biology Technology:Matrix Marketing Group Expands Client Services Team 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 2
Cached News: